Literature DB >> 22753141

Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer.

Yan Wang1, Qian-ze Dong, Ling Fu, Maggie Stoecker, Endi Wang, En-Hua Wang.   

Abstract

Crk-Like (CRKL) is an adapter protein that has crucial roles in multiple biological processes, including cell proliferation, adhesion, and migration. Amplification of CRKL gene was found in non-small cell lung cancer (NSCLC). However, the expression pattern of CRKL protein and its clinical significance in human NSCLC have not been well characterized to date. In this study, expression of CRKL was evaluated in 131 NSCLC tissues by immumohistochemistry. CRKL protein was up-regulated in the lung carcinomas compared with adjacent normal lung tissue. Overexpression of CRKL was found in 58 of 131 (44.3%) NSCLC samples and correlated with poor tumor differentiation (P = 0.0042), histological type (adenocarcinoma; P = 0.001), advanced p-TNM stage (P = 0.0004), nodal metastasis (P = 0.0273), high proliferation index (P = 0.0062) and poor overall survival (P = 0.0084). Further univariate and multivariate analysis showed a significant association of CRKL overexpression and worse overall survival in lung cancer patients. In addition, overexpression of CRKL in HBE and H1299 cell lines promoted cell proliferation by facilitating cell cycle progression. Further analysis of cell cycle related molecules showed that CRKL induced cyclin D1, cyclin B1 expression, and increased Rb phosphorylation. In conclusion, this study demonstrated overexpression of CRKL correlated with poor prognosis and lung cancer proliferation by cell cycle regulation.
© 2012 Wiley Periodicals, Inc.

Entities:  

Keywords:  CRKL; NSCLC; cyclin; immunohistochemistry; prognosis

Mesh:

Substances:

Year:  2012        PMID: 22753141     DOI: 10.1002/mc.21935

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  19 in total

1.  The association of Crk-like adapter protein with poor prognosis in glioma patients.

Authors:  Chengjun Yao; Shunzeng Lv; Mingzhi Han; Jie Zhang; Ya Zhang; Li Zhang; Ruiyang Yi; Dongxiao Zhuang; Jinsong Wu
Journal:  Tumour Biol       Date:  2014-02-22

2.  Expression level of CRKL and AXL combined with exon 19 deletion in EGFR and ALK status confer differential prognosis of lung adenocarcinoma subtypes.

Authors:  Yi-Ran Cai; Yu-Jie Dong; Hong-Bo Wu; Da-Ping Yu; Li-Juan Zhou; Dan Su; Li Zhang; Xue-Jing Chen
Journal:  Oncol Lett       Date:  2016-09-02       Impact factor: 2.967

3.  Fibroblast Growth Requires CT10 Regulator of Kinase (Crk) and Crk-like (CrkL).

Authors:  Taeju Park; Mateusz Koptyra; Tom Curran
Journal:  J Biol Chem       Date:  2016-11-02       Impact factor: 5.157

4.  SIRT4 inhibits malignancy progression of NSCLCs, through mitochondrial dynamics mediated by the ERK-Drp1 pathway.

Authors:  L Fu; Q Dong; J He; X Wang; J Xing; E Wang; X Qiu; Q Li
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

5.  Overexpression of CRKL correlates with malignant cell proliferation in breast cancer.

Authors:  Tingting Zhao; Zhifeng Miao; Zhenning Wang; Yingying Xu; Jianhua Wu; Xingyu Liu; Yi You; Jiguang Li
Journal:  Tumour Biol       Date:  2013-05-19

6.  HCRP1 downregulation confers poor prognosis and induces chemoresistance through regulation of EGFR-AKT pathway in human gastric cancer.

Authors:  Hao Xu; Zhi-Feng Miao; Zhen-Ning Wang; Ting-Ting Zhao; Ying-Ying Xu; Yong-Xi Song; Jin-Yu Huang; Jun-Yan Zhang; Xing-Yu Liu; Jian-Hua Wu; Hui-Mian Xu
Journal:  Virchows Arch       Date:  2017-09-29       Impact factor: 4.064

7.  Clinical significance and biological roles of CRKL in human bladder carcinoma.

Authors:  Bin Han; Lan Luan; Zhenqun Xu; Bin Wu
Journal:  Tumour Biol       Date:  2013-12-28

8.  The clinical implications of Crk-like adaptor protein expression in papillary thyroid microcarcinoma.

Authors:  Xiangshan Yang; Wenyuan Lv; Ranran Shi; Shaomei Cheng; Jing Zhang; Zhongfa Xu
Journal:  Tumour Biol       Date:  2014-09-04

9.  CRKL oncogene is downregulated by p53 through miR-200s.

Authors:  Miyuki Tamura; Yasushi Sasaki; Kenta Kobashi; Kousuke Takeda; Takafumi Nakagaki; Masashi Idogawa; Takashi Tokino
Journal:  Cancer Sci       Date:  2015-07-14       Impact factor: 6.716

Review 10.  Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application.

Authors:  Xun Yuan; Hua Wu; Na Han; Hanxiao Xu; Qian Chu; Shiying Yu; Yuan Chen; Kongming Wu
Journal:  J Hematol Oncol       Date:  2014-12-05       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.